Plasma Components which Interfere with Ristocetin-induced Platelet Aggregation

Summary

Normal human plasma contains a component or components which interfere with ristocetin-induced platelet aggregation. Preliminary examination suggests a protein (or proteins) which binds ristocetin and competes more effectively for ristocetin than do the proteins involved in ristocetin-induced platelet aggregation. The presence of this protein in normal human plasma also prevents ristocetin-induced precipitation of plasma proteins at levels of ristocetin necessary to produce platelet aggregation (0.5–2.0 mg/ml). Serum contains an apparent two-fold increase of this component when compared with plasma. Heating serum at 56° for one hour results in an additional 2 to 4 fold increase. The presence of a ristocetin-binding protein in normal human plasma requires that this protein be saturated with ristocetin before ristocetin-induced platelet aggregation will occur. Variations in the ristocetin-binding protein(s) will cause apparent discrepancies in ristocetin-induced platelet aggregation in normal human plasmas.

• References

• 1 Barrow E. M, Graham J. B. Blood coagulation factor VIII (antihemophilic factor) with comments on von Willebrand’s disease and Christmas disease. Physiological Reviews 1974; 54: 23
• 2 Baugh R. F, Brown J, Sargeant R, Hougie C. Separation of human factor VIII activity from von Willebrand’s antigen and ristocetin platelet aggregating activity. Biochimica et Biophysica Acta 1974; 371: 360
• 3 Hougie C, Sargeant R, Brown J. E, Baugh R. F. Evidence that Factor VIII and the ristocetin aggregating factor (VIII_Rist) are separate molecular entities. Proceedings of the Society of Experimental Biology and Medicine 1974; 147: 58
• 4 Howard M. A, Firkin G. F. Ristocetin – a new tool in the investigation of platelet aggregation. Thrombosis 1971; 26: 362
• 5 Howard M. A, Sawers R. J, Firkin B. G. Ristocetin: a means of differentiating von Willebrand’s disease into two groups. Blood 1973; 41: 687
• 6 Laurell C. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analytical Biochemistry 1960; 15: 45
• 7 Pool J. G, Shannon A. W. Production of high-potency concentrates of antihemophilic globulin in a closed bag system. New England Journal of Medicine 1965; 273: 1443
• 8 Walsh P. N. Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities. British Journal of Hematology 1972; 22: 205
• 9 Weiss H, Rogers J, Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand’s disease and its correction by factor VIII. Journal of Clinical Investigation 1973; 52: 2697
• 10 Weiss H. J, Hoyer L, Rickles R, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand’s disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. Journal of Clinical Investigation 1973; 52: 2708
• 11 Zimmerman T, Ratnoff O, Powell A. E. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand’s disease. Journal of Clinical Investigation 1971; 50: 244